Dextofisopam: Completed Phase IIb enrollment

Pharmos completed enrollment of about 324 patients in an ongoing, double-blind, U.S. Phase IIb trial comparing 100, 200 and 300 mg of dextofisopam given twice daily vs. placebo for 12 weeks. Additiona...